Viracta Therapeutics, Inc. (VIRX) gute Aussichten

Nach der Fusionierung mit SNSS geht es hier weiter.
Gestern sehr starker Tag +15%

Oppenheimer sehr positiv:
Viracta Therapeutics (VIRX) PT Raised to $36 at Oppenheimer,  

bleib ich mal dabei

If Janssen decides to exclusively license VXRT's technology on a worldwide basis for its oral influenza vaccine, it could cause a BIG stock price jump. As of 3/4/21, Janssen STILL states that it's working on an oral influenza vaccine with Vaxart

www.jnj.com/innovation/...ge-how-we-prevent-and-treat-the-flu

Vorbörse
6.17 +0.25 (4.22%)
Pre-Market: 4:25AM EST
Jetzt am Börsenspiel teilnehmen!
Melden
 

finde keine neuen News  

...business under the Viracta moniker and intends to be listed on the Nasdaq under the ticker symbol “VIRX.” Combined company is expected to have ~$120M cash balance, with an expected cash runway into 2024. The pipeline will be led by Viracta’s lead program for Epstein-Barr
 

sorry, meine Geduld ist am Ende, weg mit Schaden  

https://www.analystratings.com/articles/...d-iqvia-holdings-nyse-iqv/  

 

 

Cash Position – Cash and cash equivalents totaled approximately $103.6 million as of December 31, 2021, which Viracta expects will be sufficient to fund its operations into mid-2024, excluding any additional borrowings under the $50.0 million credit facility.

Cash bis Mitte 2024. Cash >> Market Cap



https://viracta.investorroom.com/...s-and-Provides-a-Corporate-Update  

https://www.finanzen.net/aktien/...ta_therapeutics-aktie@stBoerse_NDB  

https://www.nasdaq.com/de/market-activity/stocks/virx/real-time